| scholarly article | Q13442814 |
| P50 | author | Nazareno Paolocci | Q42067397 |
| Carlo Gabriele Tocchetti | Q42661613 | ||
| Gizem Keceli | Q52695501 | ||
| P2093 | author name string | David A Kass | |
| Dong I Lee | |||
| James E Mahaney | |||
| John P Toscano | |||
| Jeffrey P Froehlich | |||
| Carlota Sumbilla | |||
| Christopher M Pavlos | |||
| Abiona J Redwood | |||
| Russell Goldstein | |||
| P433 | issue | 50 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 13150-13152 | |
| P577 | publication date | 2008-12-01 | |
| P1433 | published in | Biochemistry | Q764876 |
| P1476 | title | Phospholamban thiols play a central role in activation of the cardiac muscle sarcoplasmic reticulum calcium pump by nitroxyl. | |
| P478 | volume | 47 |
| Q64258422 | A Phase 1 Randomized Study of Single Intravenous Infusions of the Novel Nitroxyl Donor BMS-986231 in Healthy Volunteers |
| Q38693298 | A Phase 2a dose-escalation study of the safety, tolerability, pharmacokinetics and haemodynamic effects of BMS-986231 in hospitalized patients with heart failure with reduced ejection fraction. |
| Q88956991 | A recent history of nitroxyl chemistry, pharmacology and therapeutic potential |
| Q28482269 | Acyloxy nitroso compounds inhibit LIF signaling in endothelial cells and cardiac myocytes: evidence that STAT3 signaling is redox-sensitive |
| Q47387978 | Apelin-13 limits infarct size and improves cardiac postischemic mechanical recovery only if given after ischemia. |
| Q37851240 | Cardiac inotropes: current agents and future directions |
| Q64276444 | Coding sequences of sarcoplasmic reticulum calcium ATPase regulatory peptides and expression of calcium regulatory genes in recurrent exertional rhabdomyolysis |
| Q42681487 | Direct and nitroxyl (HNO)-mediated reactions of acyloxy nitroso compounds with the thiol-containing proteins glyceraldehyde 3-phosphate dehydrogenase and alkyl hydroperoxide reductase subunit C. |
| Q35395918 | Effects of increased systolic Ca²⁺ and phospholamban phosphorylation during β-adrenergic stimulation on Ca²⁺ transient kinetics in cardiac myocytes. |
| Q37204272 | HNO enhances SERCA2a activity and cardiomyocyte function by promoting redox-dependent phospholamban oligomerization |
| Q24595118 | Heart failure with preserved ejection fraction: emerging drug strategies |
| Q39234570 | Hydroxylamine acutely activates glucose uptake in L929 fibroblast cells |
| Q59129621 | Intravenous Infusion of the Novel HNO Donor BMS-986231 Is Associated With Beneficial Inotropic, Lusitropic, and Vasodilatory Properties in 2 Canine Models of Heart Failure |
| Q34582867 | Lethal Arg9Cys phospholamban mutation hinders Ca2+-ATPase regulation and phosphorylation by protein kinase A. |
| Q49501122 | Nitric oxide signalling in cardiovascular health and disease. |
| Q39425650 | Nitroxyl (HNO) acutely activates the glucose uptake activity of GLUT1. |
| Q38224809 | Nitroxyl (HNO) for treatment of acute heart failure |
| Q34233761 | Nitroxyl (HNO) stimulates soluble guanylyl cyclase to suppress cardiomyocyte hypertrophy and superoxide generation |
| Q92177044 | Nitroxyl (HNO) targets phospholamban cysteines 41 and 46 to enhance cardiac function |
| Q26771830 | Nitroxyl (HNO): A Reduced Form of Nitric Oxide with Distinct Chemical, Pharmacological, and Therapeutic Properties |
| Q33946688 | Nitroxyl (HNO): A novel approach for the acute treatment of heart failure |
| Q34615204 | Nitroxyl activates SERCA in cardiac myocytes via glutathiolation of cysteine 674. |
| Q34671389 | Nitroxyl enhances myocyte Ca2+ transients by exclusively targeting SR Ca2+-cycling |
| Q36314776 | Nitroxyl-mediated disulfide bond formation between cardiac myofilament cysteines enhances contractile function. |
| Q26765793 | Novel Perspectives in Redox Biology and Pathophysiology of Failing Myocytes: Modulation of the Intramyocardial Redox Milieu for Therapeutic Interventions-A Review Article from the Working Group of Cardiac Cell Biology, Italian Society of Cardiology |
| Q36573243 | Pharmacological characterization of 1-nitrosocyclohexyl acetate, a long-acting nitroxyl donor that shows vasorelaxant and antiaggregatory effects. |
| Q42496988 | Phosphodiesterase type-2 and NO-dependent S-nitrosylation mediate the cardioinhibition of the antihypertensive catestatin |
| Q54722817 | Phospholamban S-nitrosylation modulates Starling response in fish heart. |
| Q37998559 | Phospholamban and cardiac function: a comparative perspective in vertebrates. |
| Q34735841 | Playing with cardiac "redox switches": the "HNO way" to modulate cardiac function |
| Q35579502 | Reversal of isoflurane-induced depression of myocardial contraction by nitroxyl via myofilament sensitization to Ca2+ |
| Q34892722 | Soluble guanylate cyclase is required for systemic vasodilation but not positive inotropy induced by nitroxyl in the mouse. |
| Q37432633 | Synthesis and chemical and biological comparison of nitroxyl- and nitric oxide-releasing diazeniumdiolate-based aspirin derivatives |
| Q35499828 | The Effect of SERCA1b Silencing on the Differentiation and Calcium Homeostasis of C2C12 Skeletal Muscle Cells |
| Q38935734 | The chemical biology of HNO signaling |
| Q37281633 | The effects of nitroxyl (HNO) on H₂O₂ metabolism and possible mechanisms of HNO signaling |
| Q37385327 | The emergence of nitroxyl (HNO) as a pharmacological agent. |
| Q42858896 | The new HNO donor, 1-nitrosocyclohexyl acetate, increases contractile force in normal and β-adrenergically desensitized ventricular myocytes |
| Q43123682 | The shy Angeli and his elusive creature: the HNO route to vasodilation |
| Q34756677 | The specificity of nitroxyl chemistry is unique among nitrogen oxides in biological systems. |
| Q38827338 | Therapeutic Potential of Nitroxyl (HNO) Donors in the Management of Acute Decompensated Heart Failure |
| Q90212284 | Tracking nitroxyl-derived posttranslational modifications of phospholamban in cardiac myocytes |
| Q89620118 | Unbalance Between Sarcoplasmic Reticulum Ca2 + Uptake and Release: A First Step Toward Ca2 + Triggered Arrhythmias and Cardiac Damage |
Search more.